Skip to main content

Table 2 Comparison between group of patients with normal overall Montreal score and those patients with abnormal score

From: Chemotherapy-induced cognitive impairment in hematological malignancies

  Overall Montreal score Chi-square
Normal Cognitive impairment
N % N % χ 2 p value
Sex Male 40 70.18 57 61.29 1.22 0.26
Female 17 29.82 36 38.71
Diagnosis AML 17 29.82 28 30.11 14.91 0.02
ALL 8 14.04 7 7.53
CML 11 19.30 5 5.38
CLL 6 10.53 14 15.05
MDS 0 0.00 2 2.15
Lymphoma 4 7.02 21 22.58
Myeloma 11 19.30 16 17.20
Chemotherapy Intensified protocol 23 40.35 33 35.48 5.76 0.12
TKIs 8 14.04 5 5.38
Velcade 11 19.30 16 17.20
Others 15 26.32 39 41.94
Route of chemotherapy Oral 10 17.54 5 5.38 5.81 0.01
Parenteral 47 82.46 88 94.62
Comorbidities No 53 92.98 51 54.84 26.52 < 0.001
HTN 0 0.00 16 17.20
DM 2 3.51 8 8.60
Viral hepatic infection 2 3.51 6 6.45
More than one 0 0.00 12 12.90
Remission status Remitted 42 73.68 61 65.59 1.07 0.30
Resistant or refractory 15 26.32 32 34.41